Previous Close | 4.7200 |
Open | 4.8000 |
Bid | 4.8200 x 300000 |
Ask | 5.0000 x 300000 |
Day's Range | 4.8000 - 4.8000 |
52 Week Range | 4.0600 - 5.4000 |
Volume | |
Avg. Volume | 28 |
Market Cap | 38.859M |
Beta (5Y Monthly) | 0.61 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.7000 |
Earnings Date | May 14, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Conference Call Scheduled for Wednesday, May 15, 2024 at 9:00 AM ETPORTLAND, Maine, May 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2024 after the market closes on Tuesday, May 14, 2024.
PORTLAND, Maine, April 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024. Preliminary, Unaudited Total Sales Results: 20242023$ Increase % IncreaseDuring the T
ImmuCell Corporation (NASDAQ:ICCC) Q4 2023 Earnings Call Transcript February 28, 2024 ImmuCell Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome to the ImmuCell Corporation reports Fourth Quarter and Year Ended December 31, 2023 Unaudited Financial […]